PepGen Inc. (NASDAQ:PEPG – Free Report) – Analysts at Wedbush lowered their FY2023 EPS estimates for PepGen in a note issued to investors on Wednesday, November 8th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($3.38) for the year, down from their prior estimate of ($3.22). The consensus estimate for PepGen’s current full-year earnings is ($3.43) per share. Wedbush also issued estimates for PepGen’s Q3 2024 earnings at ($1.04) EPS, FY2024 earnings at ($4.08) EPS and FY2025 earnings at ($4.28) EPS.
Separately, HC Wainwright restated a “buy” rating and set a $26.00 price objective on shares of PepGen in a research note on Thursday, September 7th.
PepGen Price Performance
Shares of PEPG opened at $3.86 on Monday. The business’s fifty day moving average price is $5.35 and its 200 day moving average price is $8.51. PepGen has a 12-month low of $3.72 and a 12-month high of $20.00. The stock has a market capitalization of $91.91 million, a PE ratio of -1.12 and a beta of 1.10.
PepGen (NASDAQ:PEPG – Get Free Report) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.10).
Hedge Funds Weigh In On PepGen
Large investors have recently added to or reduced their stakes in the company. UBS Group AG lifted its stake in PepGen by 34.8% in the first quarter. UBS Group AG now owns 5,453 shares of the company’s stock valued at $67,000 after buying an additional 1,407 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in PepGen by 146.9% in the first quarter. Tower Research Capital LLC TRC now owns 2,528 shares of the company’s stock valued at $31,000 after buying an additional 1,504 shares during the last quarter. Alliancebernstein L.P. lifted its stake in PepGen by 19.4% in the second quarter. Alliancebernstein L.P. now owns 12,060 shares of the company’s stock valued at $108,000 after buying an additional 1,960 shares during the last quarter. Rhumbline Advisers lifted its stake in PepGen by 11.8% in the first quarter. Rhumbline Advisers now owns 18,810 shares of the company’s stock valued at $230,000 after buying an additional 1,979 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in PepGen by 6.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 38,489 shares of the company’s stock valued at $471,000 after buying an additional 2,253 shares during the last quarter. 71.80% of the stock is currently owned by institutional investors.
PepGen Company Profile
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that id in Phase I clinical trial to treat individuals with Duchenne muscular dystrophy (DMD).
- Five stocks we like better than PepGen
- What Does a Stock Split Mean?
- MarketBeat Week in Review – 11/6 – 11/10
- Roth IRA Calculator: Calculate Your Potential Returns
- Data giants MongoDB and Snowflake just got upgraded
- Upcoming IPO Stock Lockup Period, Explained
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.